180 related articles for article (PubMed ID: 10543325)
41. Erythropoietin, folic acid deficiency and hyperhomocysteinemia: is there a possible relationship in chronically hemodialyzed patients?
Korzets A; Ori Y; Chagnac A; Weinstein T; Herman M; Zevin D; Malachi T; Gafter U
Clin Nephrol; 2000 Jan; 53(1):48-54. PubMed ID: 10661482
[TBL] [Abstract][Full Text] [Related]
42. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.
Costa E; Pereira BJ; Rocha-Pereira P; Rocha S; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252
[TBL] [Abstract][Full Text] [Related]
43. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
Tarng DC; Hung SC; Huang TP
J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
[TBL] [Abstract][Full Text] [Related]
44. Soluble CD23 in allergic diseases.
Rogala B; Rymarczyk B
Arch Immunol Ther Exp (Warsz); 1999; 47(4):251-5. PubMed ID: 10483874
[TBL] [Abstract][Full Text] [Related]
45. [Relation between serum leptin levels, blood parameters and erythropoietin levels in hemodialyzed patients].
Haluzík M; Marková M; Sulková S; Haluzíková D; Svobodová J; Bednárová V; Jiskra J
Cas Lek Cesk; 2000 Nov; 139(23):731-4. PubMed ID: 11191744
[TBL] [Abstract][Full Text] [Related]
46. Assessment of immune status in relation to vitamin D levels in children on regular hemodialysis.
Youssef DM; Elshal AS; Abo Elazem AA
Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):267-73. PubMed ID: 22382217
[TBL] [Abstract][Full Text] [Related]
47. T-cell activation modified by parathyroid hormone (PTH) in patients with end-stage renal disease.
Kaneko T; Osono E; Hayama N; Lino Y; Terashi A
Clin Nephrol; 1997 Dec; 48(6):353-8. PubMed ID: 9438093
[TBL] [Abstract][Full Text] [Related]
48. T cells and B cells in chronic renal failure.
Descamps-Latscha B; Chatenoud L
Semin Nephrol; 1996 May; 16(3):183-91. PubMed ID: 8734461
[TBL] [Abstract][Full Text] [Related]
49. Enhancement of soluble CD23 serum levels and cell-surface CD23-expression in subjects at increased risk of type 1 diabetes mellitus and in diabetic patients.
Avanzini MA; Vitali L; d'Annunzio G; De Amici M; Strigazzi C; Alibrandi A; Lorini R
Diabet Med; 1998 Apr; 15(4):320-6. PubMed ID: 9585398
[TBL] [Abstract][Full Text] [Related]
50. Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis.
Descamps-Latscha B; Herbelin A; Nguyen AT; de Groote D; Chauveau P; Verger C; Jungers P; Zingraff J
Kidney Int; 1993 Apr; 43(4):878-84. PubMed ID: 8479124
[TBL] [Abstract][Full Text] [Related]
51. Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium.
Schiffl H; Lang SM
Eur J Med Res; 1997 Mar; 2(3):97-100. PubMed ID: 9113497
[TBL] [Abstract][Full Text] [Related]
52. Acute effects of dialysis on T lymphocytes in patients with end-stage renal disease.
Chandy KG; Pahl M; Vaziri ND; Gupta S
J Clin Lab Immunol; 1985 Jul; 17(3):119-24. PubMed ID: 3930749
[TBL] [Abstract][Full Text] [Related]
53. [Serum soluble CD23 and soluble CD25 in bronchial asthmatic patients].
Shiota Y; Sato T; Ono T; Kaji M
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Aug; 31(8):932-5. PubMed ID: 8230890
[TBL] [Abstract][Full Text] [Related]
54. Serum soluble CD23 levels and CD23 expression on peripheral blood mononuclear cells in juvenile chronic arthritis.
Massa M; Pignatti P; Oliveri M; De Amici M; De Benedetti F; Martini A
Clin Exp Rheumatol; 1998; 16(5):611-6. PubMed ID: 9779313
[TBL] [Abstract][Full Text] [Related]
55. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations.
Steffensen G; Aunsholt NA; Povlsen JV
Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537
[TBL] [Abstract][Full Text] [Related]
56. Circulating serum levels of soluble CD23 (sCD23) after renal transplantation.
Traindl O; Gisinger C; Reading S; Rosenkranz AR; Zlabinger GJ
Clin Transplant; 1994 Apr; 8(2 Pt 1):87-92. PubMed ID: 8019027
[TBL] [Abstract][Full Text] [Related]
57. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses.
Meuer SC; Hauer M; Kurz P; Meyer zum Büschenfelde KH; Köhler H
J Clin Invest; 1987 Sep; 80(3):743-9. PubMed ID: 3497950
[TBL] [Abstract][Full Text] [Related]
58. Production of soluble CD23 from peripheral blood lymphocytes of asthmatic patients.
Monteseirín J; Llamas E; Muñoz F; Bandrés F; Bono MJ; Conde J
Allergol Immunopathol (Madr); 1993; 21(2):75-8. PubMed ID: 8337992
[TBL] [Abstract][Full Text] [Related]
59. [The effect of recombinant human erythropoietin during hemodialysis on the thrombocyte and erythrocyte functions of patients with chronic kidney failure].
Rud'ko IA; Balashova TS; Kubatiev AA; Ermolenko VM
Ter Arkh; 1994; 66(6):57-60. PubMed ID: 7940371
[TBL] [Abstract][Full Text] [Related]
60. Reticulocyte maturity index reflects erythropoietin effects in hemodialysis patients.
Han YS; Kishimoto T
Osaka City Med J; 1997 Jun; 43(1):69-76. PubMed ID: 9343995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
